PDF

Amira Pharmaceuticals to Present
at
the BIOCOM Investor Conference in San Diego

San Diego, CA - October 22, 2009 -- Amira Pharmaceuticals, Inc., a small molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory disease, announced today that Robert Baltera, Chief Executive Officer, will present at the 4th Annual BIOCOM Investor Conference. The presentation is scheduled for 11 a.m. PDT on Tuesday, October 27, at the Hyatt Regency La Jolla in San Diego, Calif. The BIOCOM Investor Conference includes presentations from top companies from throughout the Southwest.

About Amira

Founded in 2005 and headquartered in San Diego, Amira Pharmaceuticals is a small molecule pharmaceutical company focused on the discovery and early development of compounds to treat inflammatory disease linked to the phospholipid pathways. Amira has a strategic partnership with GlaxoSmithKline for the development of FLAP (5-lipoxygenase activating protein) inhibitors in respiratory and cardiovascular disease.

Amira combines the rigor of a big pharmaceutical company with the ingenuity and energy of a small company, creating an environment for efficient and effective pre-clinical and clinical program decisions. Its scientific founders have successfully worked together for more than a decade and were pivotal in the discovery of a number of inflammatory drugs, including Singulair®. The drug hunters at Amira are now actively leveraging their history